Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Huijuan Li
Observed name:
H. Li
Institutions:
Chinese Academy of Sciences,
South China Sea Institute Of Oceanology,
University of Chinese Academy of Sciences
Observed institutions:
University of Copenhagen,
Merck & Co., Inc., Rahway, NJ, USA (United States),
Chinese Academy of Sciences,
South China Sea Institute Of Oceanology,
University of Chinese Academy of Sciences
ORCID:
0009-0000-6289-1767
Observed ORCID:
0009-0000-6289-1767
OpenAlex ID:
A5111875486
Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose
2004
·
P. Bobrowicz
, Robert C Davidson
, et al.
·
Glycobiology
·
173
Identification of a New Family of Genes Involved in β-1,2-Mannosylation of Glycans in Pichia pastoris and Candida albicans
2008
·
Céline Mille
, Piotr Bobrowicz
, et al.
·
Journal of Biological Chemistry
·
107
PDF
Production of sialylated O-linked glycans in Pichia pastoris
2013
·
S. R. Hamilton
, W. J. Cook
, et al.
·
Glycobiology
·
65
Functional analysis of the ALG3 gene encoding the Dol-P-Man: Man5GlcNAc2-PP-Dol mannosyltransferase enzyme of P. pastoris
2004
·
R. C. Davidson
, Juergen H Nett
, et al.
·
Glycobiology
·
62
Elimination of -mannose glycan structures in Pichia pastoris
2011
·
D. Hopkins
, S. Gomathinayagam
, et al.
·
Glycobiology
·
38
The role of noncoding RNAs in bacterial immunity
2024
·
David Mayo-Muñoz
, Huijuan Li
, et al.
·
Trends in Microbiology
·
16
Structural elucidation of an -1,2-mannosidase resistant oligosaccharide produced in Pichia pastoris
2011
·
S. Gomathinayagam
, T. Mitchell
, et al.
·
Glycobiology
·
12
Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2024
·
Fei Xiao
, Kailiang Wang
, et al.
·
Molecular Cancer Therapeutics
·
10
Epoxide-Mediated Carbon Dioxide Coupling Yields the Five-Membered Cyclic Carbonate in Cytosporin Biosynthesis
2026
·
Hua Xiao
, Yong He
, et al.
·
Journal of the American Chemical Society
·
1
465 (PB453): RGT-264 a highly potent, selective and orally bioavailable HPK1 (MAP4K1) inhibitor augments immune activation and anti-tumor immunity
2024
·
F. Xiao
, H. Liu
, et al.
·
European Journal of Cancer
·
1
Cost-effectiveness Analysis of Pembrolizumab in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Cancer in England
2018
·
E. Tsoumani
, K. D'Oca
, et al.
·
Value in Health
·
1
PDF
Data from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2026
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Figure 1 from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2026
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Figure 5 from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2026
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Figure 4 from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2026
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Figure 2 from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2026
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Figure 3 from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2026
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Data File from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2024
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Tables from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2024
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Figure 5 from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2024
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Figure 2 from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2024
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Figure 3 from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2024
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Figure 1 from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2024
·
Fei Xiao
, Kailiang Wang
, et al.
Supplementary Figure 4 from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
2024
·
Fei Xiao
, Kailiang Wang
, et al.
Show more works
View as search
Works count:
24
Citation count:
486
H-index:
8
I10-index:
8
Year
Topic
Type